透過您的圖書館登入
IP:18.117.109.149
  • 期刊

VMAT治療於體重差異下肺癌患者之輻射劑量評估

Evaluating Radiation Dose for Different Body-weighted Lung Cancer Patients by VMAT Treatment

摘要


利用體重差異下的假體進行肺癌治療,經由弧形調控放射治療(Volumetric Modulated Arc Therapy, VMAT),評估器官等價劑量與有效劑量。五種體重差異的假體模擬肺癌的患者。估算有效劑量,使用熱發光劑量計(Thermoluminesent dosimeters, TLD-100H)經過Axesse 6 MV的光子,靈敏度篩選和線性校準後,佈值於侖道假體(Alderson Radiation Therapy phantom, ART Rando phantom),及自製研發壓克力(Polymethylmethacrylate, PMMA)假體,體重範圍由10公斤至90公斤重。有效劑量之推算於國際放射防護委員會(International Commission on Radiological Protection, ICRP)60及103號報告,分別為2.55±0.83 至0.74±0.26 mSv/Gy與2.65±0.74至0.84±0.26 mSv/Gy。另外,經由皮膚劑量分佈的表現上,在侖道假體中,距離腫瘤中心外5公分處,急降至處方劑量的7.73%,30公分處的第27層假體,降至處方劑量的0.51%。此研究之結果,證明VMAT治療肺癌病患,於周圍正常器官傷害很小,可減少非必要的輻射。

並列摘要


Evaluating effective doses (E) and organ or tissue equivalent dose (H_T) using different body-weight phantoms undergoing Volumetric Modulated Arc Therapy (VMAT) for lung cancer. Five polymethylmethacrylate (PMMA) and Rando phantoms that body weighted ranged from 10 kg to 90 kg were used to simulate lung cancer patients using the thermoluminescent dosimter (TLD-100H) approach. TLD-100H was calibrated using 6 MV photons coming from the Axesse linac. E values of these phantoms were 2.55±0.83 to 0.74±0.26 mSv/Gy and 2.65±0.74 to 0.84±0.26 mSv/Gy during lung cancer treatment recommended by ICRP 60 and 103, respectively. Also, the dose at 5 cm from the tumor center was abruptly down to 7.73 % of the total target dose, and this dose declined to 0.51% at 30 cm of the 27^(th) slice of Rando phantom with skin dose distributions. This results prove that the lung cancer patients will prevent unnecessary radiation at peripheral normal organs undergoing VMAT treatment.

延伸閱讀